Therapeutic strategies targeting the LPS signaling and cytokines

Andreu Ballester, 2008, Epidemiology of sepsis in the Valencian Community (Spain), 1995–2004, Infect. Control Hosp. Epidemiol., 29, 630, 10.1086/589583 Padkin, 2003, Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland, Crit. Care Med., 31, 2332, 10.1097/01.CCM.0000085141.75513.2B Angus, 2001, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care, Crit. Care Med., 29, 1303, 10.1097/00003246-200107000-00002 Braude, 1963, The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis, J. Immunol., 90, 297, 10.4049/jimmunol.90.2.297 Marshall, 2004, Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study, J. Infect. Dis., 190, 527, 10.1086/422254 Lepper, 2002, Clinical implications of antibiotic-induced endotoxin release in septic shock, Intensive Care Med., 28, 824, 10.1007/s00134-002-1330-6 Andreasen, 2008, Human endotoxemia as a model of systemic inflammation, Curr. Med. Chem., 15, 1697, 10.2174/092986708784872393 Poli-de-Figueiredo, 2008, Experimental models of sepsis and their clinical relevance, Shock Nahra, 2008, Targeting the lipopolysaccharides: still a matter of debate?, Curr. Opin. Anaesthesiol., 21, 98, 10.1097/ACO.0b013e3282f5335c Opal, 2007, The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis, Int. J. Med. Microbiol., 297, 365, 10.1016/j.ijmm.2007.03.006 Lu, 2008, LPS/TLR4 signal transduction pathway, Cytokine, 42, 145, 10.1016/j.cyto.2008.01.006 Karima, 1999, The molecular pathogenesis of endotoxic shock and organ failure, Mol. Med. Today, 5, 123, 10.1016/S1357-4310(98)01430-0 Leon, 2008, Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases, Pharm. Res., 25, 1751, 10.1007/s11095-008-9571-x Mullarkey, 2003, Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist, J. Pharmacol. Exp. Ther., 304, 1093, 10.1124/jpet.102.044487 Lynn, 2003, Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia, J. Infect. Dis., 187, 631, 10.1086/367990 Solomon, 2006, Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection, J. Infect. Dis., 193, 634, 10.1086/500147 Figueiredo, 2008, Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in equine whole blood and monocytes, Am. J. Vet. Res., 69, 796, 10.2460/ajvr.69.6.796 Bennett-Guerrero, 2007, A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass, Anesth. Analg., 104, 378, 10.1213/01.ane.0000253501.07183.2a Ishii, 2006, ‘Toll’ gates for future immunotherapy, Curr. Pharm. Des., 12, 4135, 10.2174/138161206778743484 Tracey, 1993, Tumor necrosis factor: an updated review of its biology, Crit. Care Med., 21, S415, 10.1097/00003246-199310001-00002 Tracey, 1987, Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog, Surg. Gynecol. Obstet., 164, 415 Christman, 1995, Strategies for blocking the systemic effects of cytokines in the sepsis syndrome, Crit. Care. Med., 23, 955, 10.1097/00003246-199505000-00027 Lorente, 2005, Neutralization of tumor necrosis factor in preclinical models of sepsis, Shock, 24, 107, 10.1097/01.shk.0000191343.21228.78 Cao, 2008, Mechanisms for a decrease in mortality of LPS-challenged mice by rhynchophylline, Chin. J. Pathophysiol., 24, 1148 Lu, 1996, Inhibitory effect of glycine upon endotoxin pyrogenicity, Chin. J. Pathophysiol., 12, 235 Ikejima, 1996, A diet containing glycine improves survival in endotoxin shock in the rat, Am. J. Physiol., 271, G97 Bruck, 2003, Glycine modulates cytokine secretion, inhibits hepatic damage and improves survival in a model of endotoxemia in mice, Liver Int., 23, 276, 10.1034/j.1600-0676.2003.00839.x Ding, 1999, Observation on the effect of Gly on the TNF and IL-1 production of monocytes stimulated by ET, Chin. Pharmacol. Bull., 15, 184 Spittler, 1999, Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression, FASEB. J., 13, 563, 10.1096/fasebj.13.3.563 Qi, 2005, Effect of glycine on endotoxin induce myocardial cell injury of isolated rat heart, Chin. Pharmacological. Bull., 21, 738 Sun, 1999, Influence of different pH and sealing of its amino terminal on the anti-endotoxin effect of glycine, Chin. J. Pathophysiol., 15, 100 Shan, 2003, Influence of glycine on LBP mRNA expression induced by LPS in the liver of rats, Chin. J. Pathophysiol., 19, 920 Xu, 2008, Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells, Am. J. Surg., 196, 139, 10.1016/j.amjsurg.2007.09.045 Zhong, 2003, L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent, Curr. Opin. Clin. Nutr. Metab. Care, 6, 229, 10.1097/00075197-200303000-00013 Wheeler, 2000, Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production, FASEB. J., 4, 476, 10.1096/fasebj.14.3.476 Froh, 2002, Molecular evidence for a glycine-gated chloride channel in macrophages and leukocytes, Am. J. Physiol. Gastrointest. Liver Physiol., 283, G856, 10.1152/ajpgi.00503.2001 Wheeler, 1999, Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine, Am. J. Physiol., 277, L952 Yang, 2001, Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality, Crit. Care Med., 29, 1201, 10.1097/00003246-200106000-00024 Croner, 2005, Intravenous glycine after cecal ligation and puncture has no effect on impaired hepatic microperfusion, leukocyte adhesion, and mortality in septic rats, Microvasc. Res., 69, 71, 10.1016/j.mvr.2005.01.001 Fukuda, 1999, Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells, J. Ethnopharmacol., 66, 227, 10.1016/S0378-8741(98)00162-7 Yang, 2006, Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF-alpha secretion, abnormal calcium cycling, and cardiac dysfunction in rats, Acta Pharmacol. Sin., 27, 173, 10.1111/j.1745-7254.2006.00257.x Li, 2006, Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice, Acta Pharmacol. Sin., 27, 1199, 10.1111/j.1745-7254.2006.00368.x Kuo, 2004, The anti-inflammatory potential of berberine in vitro and in vivo, Cancer Lett., 203, 127, 10.1016/j.canlet.2003.09.002 Zhang, 2008, Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice, Shock, 29, 617, 10.1097/SHK.0b013e318157ea14 Kang, 2002, Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, Biochem. Pharmacol., 63, 1901, 10.1016/S0006-2952(02)00982-6 Kim, 2003, Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response, Immunology, 109, 407, 10.1046/j.1365-2567.2003.01673.x Waterer, 2007, High-mobility group box 1 (HMGB1) as a potential therapeutic target in sepsis-more questions than answers, Crit. Care Med., 35, 1205, 10.1097/01.CCM.0000259171.54501.B2 Schefold, 2008, Sepsis: time has come to focus on the later stages, Med. Hypotheses, 71, 203, 10.1016/j.mehy.2008.03.022 Wang, 2008, Molecular and cellular aspects of sepsis-induced immunosuppression, J. Mol. Med., 86, 495, 10.1007/s00109-007-0300-4 Presneill, 2002, A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction, Am. J. Respir. Crit. Care Med., 166, 138, 10.1164/rccm.2009005 Qi, 2007, Glycine receptors contribute to cytoprotection of glycine in myocardial cells, Chin. Med. J. (Engl.), 120, 915, 10.1097/00029330-200705020-00012